BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 12481412)

  • 1. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW; Honsawek S; Litz J; Buchdunger E
    Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
    J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Clark AS; West K; Streicher S; Dennis PA
    Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
    Song K; Cornelius SC; Reiss M; Danielpour D
    J Biol Chem; 2003 Oct; 278(40):38342-51. PubMed ID: 12876289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G; Sailaja D
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38 MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway.
    Kumar P; Miller AI; Polverini PJ
    J Biol Chem; 2004 Oct; 279(41):43352-60. PubMed ID: 15292252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
    J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mono- or dual-phosphorylation of akt kinase is regulated by distinct receptors that involve the common insulin receptor substrate.
    Schnyder B; Lahm H; Pittet M; Schnyder-Candrian S
    J Recept Signal Transduct Res; 2002; 22(1-4):213-28. PubMed ID: 12503617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
    Brognard J; Clark AS; Ni Y; Dennis PA
    Cancer Res; 2001 May; 61(10):3986-97. PubMed ID: 11358816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.